CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 2,500 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 2,500 shares of CeriBell stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $21.89, for a total value of $54,725.00. Following the transaction, the director owned 19,576 shares in the company, valued at $428,518.64. This represents a 11.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

CeriBell Stock Up 4.4%

Shares of CeriBell stock opened at $21.73 on Wednesday. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $26.04. The company has a market cap of $806.18 million, a P/E ratio of -14.39 and a beta of 1.02. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average price of $17.33 and a 200 day moving average price of $14.97.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. As a group, analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: FDA Breakthrough Device designation for CeriBell’s LVO stroke detection/monitoring system — the designation raises the product’s regulatory profile and can accelerate review and access, supporting revenue growth and credibility with hospitals and payors. Ceribell Receives FDA Breakthrough Device Designation
• Neutral Sentiment: Multiple media/analyst outlets are reporting the designation, amplifying investor awareness and likely driving short-term trading interest without adding new technical detail. Zacks: CBLL Wins FDA Breakthrough Status
• Neutral Sentiment: Recent fundamentals: the company beat the last quarter’s revenue and EPS estimates but remains unprofitable with negative margins and analyst forecasts for negative full-year EPS — supportive for growth narrative but underscores ongoing execution and profitability risk.
• Negative Sentiment: Insider sale — CTO Raymond Woo sold 11,112 shares at an average $21.18 on Jan. 2, reducing his stake by ~6.2%; disclosed via SEC filing. Insider selling can be interpreted by some investors as a signal to trim exposure. SEC Filing: Raymond Woo
• Negative Sentiment: Insider sale — Director Rebecca B. Robertson sold 2,500 shares at an average $21.89 on Jan. 2, a roughly 11.3% reduction in her position; disclosed via SEC filing. SEC Filing: Rebecca B. Robertson

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research note on Monday, December 15th. Raymond James Financial assumed coverage on CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, TD Cowen cut their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.67.

Institutional Trading of CeriBell

Several large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter valued at approximately $33,000. Police & Firemen s Retirement System of New Jersey raised its position in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after purchasing an additional 3,502 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in shares of CeriBell by 148.6% in the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.